Expansion momentum Adams Clinical is actively expanding its neuroscience and inpatient psychiatry trial capabilities, evidenced by the 2024 partnership with InSite Clinical Research and the new Davis Clinical site in the Bronx, signaling growth opportunities for CROs and sponsors seeking broader site networks.

Leadership growth Appointment of a Chief Scientific Officer in March 2025 strengthens scientific leadership and credibility for complex CNS trials, which can be leveraged to attract sponsors prioritizing rigorous study design and advanced neuroscience programs.

Strategic funding Financing activity includes a notable investment from InTandem Capital Partners, indicating investor confidence and potential for accelerated capacity expansion, enabling more trial slots and faster project kickoffs for prospective clients.

Site network opportunity Network comprises six clinical research sites across the US focused on psychiatric and neurological conditions, presenting a compelling value proposition for sponsors seeking diverse geographic enrollment and access to specialized CNS patient populations.

Growth through partnerships Recent alliances and landlord partnerships, such as the long-term lease for a new Bronx site, point to scalable infrastructure and collaboration-ready footprint ideal for multi-site trials and accelerated site activation for new programs.